Published online September 1, 2006
PEDIATRICS Vol. 118 No. 3 September 2006, pp. e934-e963 (doi:10.1542/peds.2006-1783)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaye, C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaye, C. I.
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

TECHNICAL REPORT

Newborn Screening Fact Sheets

Celia I. Kaye, MD, PhD and the Committee on Genetics

ABSTRACT

Newborn screening fact sheets were last revised in 1996 by the American Academy of Pediatrics Committee on Genetics. This revision was prompted by advances in the field since 1996, including technologic innovations, as well as greater appreciation of ethical issues such as those surrounding informed consent. The following disorders are discussed in this revision of the newborn screening fact sheets: biotinidase deficiency, congenital adrenal hyperplasia, congenital hearing loss, congenital hypothyroidism, cystic fibrosis, galactosemia, homocystinuria, maple syrup urine disease, medium-chain acyl-coenzyme A dehydrogenase deficiency, phenylketonuria, sickle cell disease and other hemoglobinopathies, and tyrosinemia. A series of topics related to newborn screening is discussed in a companion publication to this electronic publication of the fact sheets (available at: www.pediatrics.org/cgi/content/full/118/3/1304). These topics are newborn screening as a public health system; factors contributing to the need for review of the newborn screening system; informed consent; tandem mass spectrometry; DNA analysis in newborn screening; status of newborn screening in the United States; and the effect of sample timing, preterm birth, diet, transfusion, and total parenteral nutrition on newborn screening results.

Key Words: newborn screening • screening • genetic disorder • biotinidase deficiency • congenital adrenal hyperplasia • congenital hearing loss • congenital hypothyroidism • cystic fibrosis • galactosemia • hemoglobinopathies • homocystinuria • maple syrup urine disease • medium-chain acyl-CoA dehydrogenase deficiency • phenylketonuria • sickle cell disease • tyrosinemia • tandem mass spectrometry

Abbreviations: OMIM, Online Mendelian Inheritance in Man • MS/MS, tandem mass spectrometry • CoA, coenzyme A • BTD, biotinidase gene • CAH, congenital adrenal hyperplasia • 21-OH, 21-hydroxylase • SW, salt wasting • SV, simple virilizing • AG, ambiguous genitalia • ACTH, adrenocorticotropic hormone • 17-OHP, 17-OH-progesterone • AABR, automated auditory brainstem response • OAE, otoacoustic emission • CH, congenital hypothyroidism • T4, thyroxine • HPT, hypothalamic-pituitary-thyroid • CF, cystic fibrosis • CFTR, cystic fibrosis transmembrane conductance regulator • IRT, immunoreactive trypsinogen • GALT, galactose 1-phosphate uridyltransferase • GALK, galactokinase • GALE, galactose-4'-epimerase • CBS, cystathionine ß-synthase • BIA, bacterial inhibition assay • MSUD, maple syrup urine disease • BCKD, branched-chain {alpha}-keto acid dehydrogenase • BCAA, branched-chain amino acid • BCKA, branched-chain {alpha}-keto acid • E3, dihydrolipoyl dehydrogenase • E1, thiamine pyrophosphate–dependent decarboxylase • E2, transacylase • MCAD, medium-chain acyl-coenzyme A dehydrogenase • FAO, fatty acid oxidation • SIDS, sudden infant death syndrome • ADHD, attention-deficit/hyperactivity disorder • PKU, phenylketonuria • PAH, phenylalanine hydroxylase • BH4, tetrahydrobiopterin • SCD, sickle cell disease • HPLC, high-performance liquid chromatography • Hb, hemoglobin • HbF, fetal hemoglobin • HbA, normal adult hemoglobin • FA, fetal and adult hemoglobin • MCV, mean corpuscular volume • FAH, fumarylacetoacetate hydrolase • TAT, tyrosine aminotransferase • NTBC, 2-(2-nitro-4-trifluoromethylbenzyl)-1,3-cyclohexanedione

 
 
 
 
 
 
 
 
 
 
 
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

The following policy statement has been revised:

Newborn Screening Fact Sheet
Pediatrics 98: 473-501.



This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
K. J. Wierenga, K. Lai, P. Buchwald, and M. Tang
High-Throughput Screening for Human Galactokinase Inhibitors
J Biomol Screen, June 1, 2008; 13(5): 415 - 423.
[Abstract] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
B. A. Tarini
The Current Revolution in Newborn Screening: New Technology, Old Controversies
Arch Pediatr Adolesc Med, August 1, 2007; 161(8): 767 - 772.
[Abstract] [Full Text] [PDF]